Global Short-acting Recombinant Human Erythropoietin Drugs Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at US$ 8968.6 million in 2022. With growing demand in downstream market, the Short-acting Recombinant Human Erythropoietin Drugs is forecast to a readjusted size of US$ 14070 million by 2029 with a CAGR of 6.6% during review period.
The research report highlights the growth potential of the global Short-acting Recombinant Human Erythropoietin Drugs market. Short-acting Recombinant Human Erythropoietin Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Short-acting Recombinant Human Erythropoietin Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Short-acting Recombinant Human Erythropoietin Drugs market.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
Key Features:
The report on Short-acting Recombinant Human Erythropoietin Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Short-acting Recombinant Human Erythropoietin Drugs market. It may include historical data, market segmentation by Type (e.g., Epoetin-alfa, Epoetin-beta), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Short-acting Recombinant Human Erythropoietin Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Short-acting Recombinant Human Erythropoietin Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Short-acting Recombinant Human Erythropoietin Drugs industry. This include advancements in Short-acting Recombinant Human Erythropoietin Drugs technology, Short-acting Recombinant Human Erythropoietin Drugs new entrants, Short-acting Recombinant Human Erythropoietin Drugs new investment, and other innovations that are shaping the future of Short-acting Recombinant Human Erythropoietin Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Short-acting Recombinant Human Erythropoietin Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Short-acting Recombinant Human Erythropoietin Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Short-acting Recombinant Human Erythropoietin Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Short-acting Recombinant Human Erythropoietin Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Short-acting Recombinant Human Erythropoietin Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Short-acting Recombinant Human Erythropoietin Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Short-acting Recombinant Human Erythropoietin Drugs market.
Market Segmentation:
Short-acting Recombinant Human Erythropoietin Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Short-acting Recombinant Human Erythropoietin Drugs market?
What factors are driving Short-acting Recombinant Human Erythropoietin Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Short-acting Recombinant Human Erythropoietin Drugs market opportunities vary by end market size?
How does Short-acting Recombinant Human Erythropoietin Drugs break out type, application?
According to our LPI (LP Information) latest study, the global Short-acting Recombinant Human Erythropoietin Drugs market size was valued at US$ 8968.6 million in 2022. With growing demand in downstream market, the Short-acting Recombinant Human Erythropoietin Drugs is forecast to a readjusted size of US$ 14070 million by 2029 with a CAGR of 6.6% during review period.
The research report highlights the growth potential of the global Short-acting Recombinant Human Erythropoietin Drugs market. Short-acting Recombinant Human Erythropoietin Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Short-acting Recombinant Human Erythropoietin Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Short-acting Recombinant Human Erythropoietin Drugs market.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.
Key Features:
The report on Short-acting Recombinant Human Erythropoietin Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Short-acting Recombinant Human Erythropoietin Drugs market. It may include historical data, market segmentation by Type (e.g., Epoetin-alfa, Epoetin-beta), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Short-acting Recombinant Human Erythropoietin Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Short-acting Recombinant Human Erythropoietin Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Short-acting Recombinant Human Erythropoietin Drugs industry. This include advancements in Short-acting Recombinant Human Erythropoietin Drugs technology, Short-acting Recombinant Human Erythropoietin Drugs new entrants, Short-acting Recombinant Human Erythropoietin Drugs new investment, and other innovations that are shaping the future of Short-acting Recombinant Human Erythropoietin Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Short-acting Recombinant Human Erythropoietin Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Short-acting Recombinant Human Erythropoietin Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Short-acting Recombinant Human Erythropoietin Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Short-acting Recombinant Human Erythropoietin Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Short-acting Recombinant Human Erythropoietin Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Short-acting Recombinant Human Erythropoietin Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Short-acting Recombinant Human Erythropoietin Drugs market.
Market Segmentation:
Short-acting Recombinant Human Erythropoietin Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
- Anemia
- Kidney Disorders
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Johnson & Johnson
- Roche
- Kyowa Kirin
- LG Chem
- Daewoong Pharmaceutical
- Wockhardt
- CJ Healthcare
- 3SBio
- Kexing Biopharm
- Harbin Pharmaceutical Group
- Beijing Four Rings Bio-Pharmaceutical
What is the 10-year outlook for the global Short-acting Recombinant Human Erythropoietin Drugs market?
What factors are driving Short-acting Recombinant Human Erythropoietin Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Short-acting Recombinant Human Erythropoietin Drugs market opportunities vary by end market size?
How does Short-acting Recombinant Human Erythropoietin Drugs break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Country/Region, 2018, 2022 & 2029
2.2 Short-acting Recombinant Human Erythropoietin Drugs Segment by Type
2.2.1 Epoetin-alfa
2.2.2 Epoetin-beta
2.2.3 Darbepoetin-alfa
2.2.4 Others
2.3 Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
2.3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2018-2023)
2.4 Short-acting Recombinant Human Erythropoietin Drugs Segment by Application
2.4.1 Anemia
2.4.2 Kidney Disorders
2.4.3 Others
2.5 Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
2.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2018-2023)
3 GLOBAL SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY COMPANY
3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Breakdown Data by Company
3.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2018-2023)
3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2018-2023)
3.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company
3.4 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Product Location Distribution
3.4.2 Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.4 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.6 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
5 AMERICAS
5.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country
5.1.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
5.1.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
5.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
5.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region
6.1.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018-2023)
6.1.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2018-2023)
6.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
6.3 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Short-acting Recombinant Human Erythropoietin Drugs by Country
7.1.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
7.1.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
7.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
7.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs by Country
8.1.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
8.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.3 Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.4 Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Short-acting Recombinant Human Erythropoietin Drugs Distributors
11.3 Short-acting Recombinant Human Erythropoietin Drugs Customer
12 WORLD FORECAST REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
12.1 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size Forecast by Region
12.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Region (2024-2029)
12.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Type
12.7 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Kyowa Kirin
13.4.1 Kyowa Kirin Company Information
13.4.2 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Kyowa Kirin Main Business Overview
13.4.5 Kyowa Kirin Latest Developments
13.5 LG Chem
13.5.1 LG Chem Company Information
13.5.2 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 LG Chem Main Business Overview
13.5.5 LG Chem Latest Developments
13.6 Daewoong Pharmaceutical
13.6.1 Daewoong Pharmaceutical Company Information
13.6.2 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Daewoong Pharmaceutical Main Business Overview
13.6.5 Daewoong Pharmaceutical Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 CJ Healthcare
13.8.1 CJ Healthcare Company Information
13.8.2 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 CJ Healthcare Main Business Overview
13.8.5 CJ Healthcare Latest Developments
13.9 3SBio
13.9.1 3SBio Company Information
13.9.2 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 3SBio Main Business Overview
13.9.5 3SBio Latest Developments
13.10 Kexing Biopharm
13.10.1 Kexing Biopharm Company Information
13.10.2 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Kexing Biopharm Main Business Overview
13.10.5 Kexing Biopharm Latest Developments
13.11 Harbin Pharmaceutical Group
13.11.1 Harbin Pharmaceutical Group Company Information
13.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Harbin Pharmaceutical Group Main Business Overview
13.11.5 Harbin Pharmaceutical Group Latest Developments
13.12 Beijing Four Rings Bio-Pharmaceutical
13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Short-acting Recombinant Human Erythropoietin Drugs by Country/Region, 2018, 2022 & 2029
2.2 Short-acting Recombinant Human Erythropoietin Drugs Segment by Type
2.2.1 Epoetin-alfa
2.2.2 Epoetin-beta
2.2.3 Darbepoetin-alfa
2.2.4 Others
2.3 Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
2.3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2018-2023)
2.4 Short-acting Recombinant Human Erythropoietin Drugs Segment by Application
2.4.1 Anemia
2.4.2 Kidney Disorders
2.4.3 Others
2.5 Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
2.5.1 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2018-2023)
3 GLOBAL SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY COMPANY
3.1 Global Short-acting Recombinant Human Erythropoietin Drugs Breakdown Data by Company
3.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2018-2023)
3.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2018-2023)
3.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company
3.4 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Product Location Distribution
3.4.2 Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Short-acting Recombinant Human Erythropoietin Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.4 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.5 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
4.6 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Growth
5 AMERICAS
5.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country
5.1.1 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
5.1.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
5.2 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
5.3 Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region
6.1.1 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018-2023)
6.1.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2018-2023)
6.2 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
6.3 APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Short-acting Recombinant Human Erythropoietin Drugs by Country
7.1.1 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
7.1.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
7.2 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
7.3 Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs by Country
8.1.1 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type
8.3 Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.3 Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
10.4 Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Short-acting Recombinant Human Erythropoietin Drugs Distributors
11.3 Short-acting Recombinant Human Erythropoietin Drugs Customer
12 WORLD FORECAST REVIEW FOR SHORT-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS BY GEOGRAPHIC REGION
12.1 Global Short-acting Recombinant Human Erythropoietin Drugs Market Size Forecast by Region
12.1.1 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Region (2024-2029)
12.1.2 Global Short-acting Recombinant Human Erythropoietin Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Type
12.7 Global Short-acting Recombinant Human Erythropoietin Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.1.3 Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.2.3 Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.3.3 Roche Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Kyowa Kirin
13.4.1 Kyowa Kirin Company Information
13.4.2 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.4.3 Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Kyowa Kirin Main Business Overview
13.4.5 Kyowa Kirin Latest Developments
13.5 LG Chem
13.5.1 LG Chem Company Information
13.5.2 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.5.3 LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 LG Chem Main Business Overview
13.5.5 LG Chem Latest Developments
13.6 Daewoong Pharmaceutical
13.6.1 Daewoong Pharmaceutical Company Information
13.6.2 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.6.3 Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Daewoong Pharmaceutical Main Business Overview
13.6.5 Daewoong Pharmaceutical Latest Developments
13.7 Wockhardt
13.7.1 Wockhardt Company Information
13.7.2 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.7.3 Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Wockhardt Main Business Overview
13.7.5 Wockhardt Latest Developments
13.8 CJ Healthcare
13.8.1 CJ Healthcare Company Information
13.8.2 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.8.3 CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 CJ Healthcare Main Business Overview
13.8.5 CJ Healthcare Latest Developments
13.9 3SBio
13.9.1 3SBio Company Information
13.9.2 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.9.3 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 3SBio Main Business Overview
13.9.5 3SBio Latest Developments
13.10 Kexing Biopharm
13.10.1 Kexing Biopharm Company Information
13.10.2 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.10.3 Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Kexing Biopharm Main Business Overview
13.10.5 Kexing Biopharm Latest Developments
13.11 Harbin Pharmaceutical Group
13.11.1 Harbin Pharmaceutical Group Company Information
13.11.2 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.11.3 Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Harbin Pharmaceutical Group Main Business Overview
13.11.5 Harbin Pharmaceutical Group Latest Developments
13.12 Beijing Four Rings Bio-Pharmaceutical
13.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
13.12.2 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
13.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Beijing Four Rings Bio-Pharmaceutical Main Business Overview
13.12.5 Beijing Four Rings Bio-Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Epoetin-alfa
Table 4. Major Players of Epoetin-beta
Table 5. Major Players of Darbepoetin-alfa
Table 6. Major Players of Others
Table 7. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 8. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Table 9. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Type (2018-2023) & ($ million)
Table 10. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2018-2023)
Table 11. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Table 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Application (2018-2023)
Table 15. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2018-2023)
Table 16. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Company (2018-2023) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2018-2023)
Table 19. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2018-2023)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution and Sales Area
Table 23. Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
Table 24. Short-acting Recombinant Human Erythropoietin Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Geographic Region (2018-2023)
Table 29. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2018-2023)
Table 33. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)
Table 36. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)
Table 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)
Table 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 41. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018-2023) & (K Units)
Table 42. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2018-2023)
Table 43. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2018-2023)
Table 45. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 46. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 47. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)
Table 48. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)
Table 49. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)
Table 51. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 52. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Short-acting Recombinant Human Erythropoietin Drugs
Table 60. Key Market Challenges & Risks of Short-acting Recombinant Human Erythropoietin Drugs
Table 61. Key Industry Trends of Short-acting Recombinant Human Erythropoietin Drugs
Table 62. Short-acting Recombinant Human Erythropoietin Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Short-acting Recombinant Human Erythropoietin Drugs Distributors List
Table 65. Short-acting Recombinant Human Erythropoietin Drugs Customer List
Table 66. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Amgen Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 82. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Amgen Main Business
Table 84. Amgen Latest Developments
Table 85. Johnson & Johnson Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 87. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Johnson & Johnson Main Business
Table 89. Johnson & Johnson Latest Developments
Table 90. Roche Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 92. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Roche Main Business
Table 94. Roche Latest Developments
Table 95. Kyowa Kirin Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 97. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Kyowa Kirin Main Business
Table 99. Kyowa Kirin Latest Developments
Table 100. LG Chem Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 102. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. LG Chem Main Business
Table 104. LG Chem Latest Developments
Table 105. Daewoong Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 107. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Daewoong Pharmaceutical Main Business
Table 109. Daewoong Pharmaceutical Latest Developments
Table 110. Wockhardt Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 112. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Wockhardt Main Business
Table 114. Wockhardt Latest Developments
Table 115. CJ Healthcare Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 117. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. CJ Healthcare Main Business
Table 119. CJ Healthcare Latest Developments
Table 120. 3SBio Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 122. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. 3SBio Main Business
Table 124. 3SBio Latest Developments
Table 125. Kexing Biopharm Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 127. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Kexing Biopharm Main Business
Table 129. Kexing Biopharm Latest Developments
Table 130. Harbin Pharmaceutical Group Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 132. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Harbin Pharmaceutical Group Main Business
Table 134. Harbin Pharmaceutical Group Latest Developments
Table 135. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 137. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Beijing Four Rings Bio-Pharmaceutical Main Business
Table 139. Beijing Four Rings Bio-Pharmaceutical Latest Developments
Table 1. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Short-acting Recombinant Human Erythropoietin Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Epoetin-alfa
Table 4. Major Players of Epoetin-beta
Table 5. Major Players of Darbepoetin-alfa
Table 6. Major Players of Others
Table 7. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 8. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Table 9. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Type (2018-2023) & ($ million)
Table 10. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2018-2023)
Table 11. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 12. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Table 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Application (2018-2023)
Table 15. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application (2018-2023)
Table 16. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 17. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Company (2018-2023) & (K Units)
Table 18. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company (2018-2023)
Table 19. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Company (2018-2023) ($ Millions)
Table 20. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company (2018-2023)
Table 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 22. Key Manufacturers Short-acting Recombinant Human Erythropoietin Drugs Producing Area Distribution and Sales Area
Table 23. Players Short-acting Recombinant Human Erythropoietin Drugs Products Offered
Table 24. Short-acting Recombinant Human Erythropoietin Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 28. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Geographic Region (2018-2023)
Table 29. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 30. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 31. Global Short-acting Recombinant Human Erythropoietin Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 32. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country/Region (2018-2023)
Table 33. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 34. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country/Region (2018-2023)
Table 35. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)
Table 36. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)
Table 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)
Table 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 41. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018-2023) & (K Units)
Table 42. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region (2018-2023)
Table 43. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 44. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Region (2018-2023)
Table 45. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 46. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 47. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)
Table 48. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)
Table 49. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 50. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)
Table 51. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 52. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 53. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Country (2018-2023) & (K Units)
Table 54. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country (2018-2023)
Table 55. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 56. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country (2018-2023)
Table 57. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Type (2018-2023) & (K Units)
Table 58. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales by Application (2018-2023) & (K Units)
Table 59. Key Market Drivers & Growth Opportunities of Short-acting Recombinant Human Erythropoietin Drugs
Table 60. Key Market Challenges & Risks of Short-acting Recombinant Human Erythropoietin Drugs
Table 61. Key Industry Trends of Short-acting Recombinant Human Erythropoietin Drugs
Table 62. Short-acting Recombinant Human Erythropoietin Drugs Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Short-acting Recombinant Human Erythropoietin Drugs Distributors List
Table 65. Short-acting Recombinant Human Erythropoietin Drugs Customer List
Table 66. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 67. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 68. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 69. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 70. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 71. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 77. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 79. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 80. Amgen Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Amgen Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 82. Amgen Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Amgen Main Business
Table 84. Amgen Latest Developments
Table 85. Johnson & Johnson Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 87. Johnson & Johnson Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Johnson & Johnson Main Business
Table 89. Johnson & Johnson Latest Developments
Table 90. Roche Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Roche Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 92. Roche Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Roche Main Business
Table 94. Roche Latest Developments
Table 95. Kyowa Kirin Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 97. Kyowa Kirin Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Kyowa Kirin Main Business
Table 99. Kyowa Kirin Latest Developments
Table 100. LG Chem Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 102. LG Chem Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. LG Chem Main Business
Table 104. LG Chem Latest Developments
Table 105. Daewoong Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 107. Daewoong Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Daewoong Pharmaceutical Main Business
Table 109. Daewoong Pharmaceutical Latest Developments
Table 110. Wockhardt Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 112. Wockhardt Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Wockhardt Main Business
Table 114. Wockhardt Latest Developments
Table 115. CJ Healthcare Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 117. CJ Healthcare Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. CJ Healthcare Main Business
Table 119. CJ Healthcare Latest Developments
Table 120. 3SBio Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 122. 3SBio Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. 3SBio Main Business
Table 124. 3SBio Latest Developments
Table 125. Kexing Biopharm Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 127. Kexing Biopharm Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Kexing Biopharm Main Business
Table 129. Kexing Biopharm Latest Developments
Table 130. Harbin Pharmaceutical Group Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 132. Harbin Pharmaceutical Group Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 133. Harbin Pharmaceutical Group Main Business
Table 134. Harbin Pharmaceutical Group Latest Developments
Table 135. Beijing Four Rings Bio-Pharmaceutical Basic Information, Short-acting Recombinant Human Erythropoietin Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Product Portfolios and Specifications
Table 137. Beijing Four Rings Bio-Pharmaceutical Short-acting Recombinant Human Erythropoietin Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 138. Beijing Four Rings Bio-Pharmaceutical Main Business
Table 139. Beijing Four Rings Bio-Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Short-acting Recombinant Human Erythropoietin Drugs
Figure 2. Short-acting Recombinant Human Erythropoietin Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Epoetin-alfa
Figure 10. Product Picture of Epoetin-beta
Figure 11. Product Picture of Darbepoetin-alfa
Figure 12. Product Picture of Others
Figure 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type in 2022
Figure 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2018-2023)
Figure 15. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Anemia
Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Anemia (2018-2023) & (K Units)
Figure 17. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Kidney Disorders
Figure 18. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Kidney Disorders (2018-2023) & (K Units)
Figure 19. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Others
Figure 20. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Others (2018-2023) & (K Units)
Figure 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2022)
Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application in 2022
Figure 23. Short-acting Recombinant Human Erythropoietin Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company in 2022
Figure 25. Short-acting Recombinant Human Erythropoietin Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company in 2022
Figure 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 30. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 32. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 34. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022
Figure 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022
Figure 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region in 2022
Figure 46. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 49. China Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022
Figure 57. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022
Figure 58. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs in 2022
Figure 75. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
Figure 76. Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
Figure 77. Channels of Distribution
Figure 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Short-acting Recombinant Human Erythropoietin Drugs
Figure 2. Short-acting Recombinant Human Erythropoietin Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Short-acting Recombinant Human Erythropoietin Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Epoetin-alfa
Figure 10. Product Picture of Epoetin-beta
Figure 11. Product Picture of Darbepoetin-alfa
Figure 12. Product Picture of Others
Figure 13. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type in 2022
Figure 14. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Type (2018-2023)
Figure 15. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Anemia
Figure 16. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Anemia (2018-2023) & (K Units)
Figure 17. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Kidney Disorders
Figure 18. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Kidney Disorders (2018-2023) & (K Units)
Figure 19. Short-acting Recombinant Human Erythropoietin Drugs Consumed in Others
Figure 20. Global Short-acting Recombinant Human Erythropoietin Drugs Market: Others (2018-2023) & (K Units)
Figure 21. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2022)
Figure 22. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Application in 2022
Figure 23. Short-acting Recombinant Human Erythropoietin Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Company in 2022
Figure 25. Short-acting Recombinant Human Erythropoietin Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Company in 2022
Figure 27. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 30. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 32. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 34. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022
Figure 38. Americas Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022
Figure 39. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Region in 2022
Figure 46. APAC Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 49. China Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022
Figure 57. Europe Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022
Figure 58. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Short-acting Recombinant Human Erythropoietin Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Short-acting Recombinant Human Erythropoietin Drugs in 2022
Figure 75. Manufacturing Process Analysis of Short-acting Recombinant Human Erythropoietin Drugs
Figure 76. Industry Chain Structure of Short-acting Recombinant Human Erythropoietin Drugs
Figure 77. Channels of Distribution
Figure 78. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Short-acting Recombinant Human Erythropoietin Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Short-acting Recombinant Human Erythropoietin Drugs Revenue Market Share Forecast by Application (2024-2029)
